Probi AB (publ) (PROB.ST)
SEK 348.0
(0.0%)
SEK 348.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 115.61 Million SEK | -23.27% |
| 2022 | 130.92 Million SEK | -23.24% |
| 2021 | 172.29 Million SEK | -6.29% |
| 2020 | 185.7 Million SEK | 5.62% |
| 2019 | 178.92 Million SEK | 16.39% |
| 2018 | 158.7 Million SEK | 4.68% |
| 2017 | 151.89 Million SEK | -6.38% |
| 2016 | 152 Million SEK | 149.65% |
| 2015 | 64.75 Million SEK | 48.22% |
| 2014 | 37.77 Million SEK | 89.31% |
| 2013 | 23.07 Million SEK | -6.47% |
| 2012 | 24.67 Million SEK | -14.57% |
| 2011 | 28.45 Million SEK | 3.15% |
| 2010 | 28 Million SEK | 38.58% |
| 2009 | 19.77 Million SEK | 15.7% |
| 2008 | 17.46 Million SEK | 51.34% |
| 2007 | 11.53 Million SEK | 489.93% |
| 2006 | 1.06 Million SEK | -91.85% |
| 2005 | 23.99 Million SEK | -22.61% |
| 2004 | 31 Million SEK | 57.97% |
| 2003 | 19.62 Million SEK | 33.08% |
| 2002 | 14.74 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 30.23 Million SEK | -17.24% |
| 2024 Q1 | 21.78 Million SEK | 26.91% |
| 2024 Q2 | 34.48 Million SEK | 38.94% |
| 2023 Q3 | 30.78 Million SEK | 94.78% |
| 2023 Q2 | 15.8 Million SEK | -67.29% |
| 2023 Q4 | 18.43 Million SEK | -40.12% |
| 2023 Q1 | 48.3 Million SEK | 179.44% |
| 2023 FY | - SEK | -23.27% |
| 2022 Q3 | 37.84 Million SEK | -19.33% |
| 2022 Q2 | 46.9 Million SEK | 23.32% |
| 2022 FY | - SEK | -23.24% |
| 2022 Q4 | 17.28 Million SEK | -54.32% |
| 2022 Q1 | 38.03 Million SEK | -29.28% |
| 2021 Q4 | 53.78 Million SEK | 26.87% |
| 2021 Q1 | 47.61 Million SEK | 4.56% |
| 2021 Q2 | 38.7 Million SEK | -18.73% |
| 2021 Q3 | 42.39 Million SEK | 9.53% |
| 2021 FY | - SEK | -6.29% |
| 2020 Q3 | 60.71 Million SEK | 9.7% |
| 2020 Q2 | 55.34 Million SEK | 67.0% |
| 2020 FY | - SEK | 5.62% |
| 2020 Q1 | 33.14 Million SEK | -35.65% |
| 2020 Q4 | 45.53 Million SEK | -24.99% |
| 2019 Q2 | 56.46 Million SEK | 94.22% |
| 2019 Q1 | 29.07 Million SEK | -35.35% |
| 2019 Q3 | 47.34 Million SEK | -16.16% |
| 2019 Q4 | 51.5 Million SEK | 8.79% |
| 2019 FY | - SEK | 16.39% |
| 2018 Q3 | 51.08 Million SEK | 16.7% |
| 2018 Q1 | 18.6 Million SEK | -9.17% |
| 2018 FY | - SEK | 4.68% |
| 2018 Q4 | 44.96 Million SEK | -11.96% |
| 2018 Q2 | 43.77 Million SEK | 135.33% |
| 2017 Q3 | 25.15 Million SEK | -45.9% |
| 2017 Q2 | 46.5 Million SEK | -30.14% |
| 2017 Q1 | 66.56 Million SEK | 11.13% |
| 2017 Q4 | 20.47 Million SEK | -18.6% |
| 2017 FY | - SEK | -6.38% |
| 2016 Q3 | 40.69 Million SEK | 71.13% |
| 2016 Q1 | 37.29 Million SEK | 1615.89% |
| 2016 FY | - SEK | 149.65% |
| 2016 Q4 | 59.89 Million SEK | 47.2% |
| 2016 Q2 | 23.77 Million SEK | -36.24% |
| 2015 Q3 | 19.04 Million SEK | 9.25% |
| 2015 Q2 | 17.43 Million SEK | -43.28% |
| 2015 Q4 | -2.46 Million SEK | -112.92% |
| 2015 FY | - SEK | 48.22% |
| 2015 Q1 | 30.73 Million SEK | 118.11% |
| 2014 Q4 | 14.09 Million SEK | 29.64% |
| 2014 FY | - SEK | 89.31% |
| 2014 Q3 | 10.87 Million SEK | 52.11% |
| 2014 Q2 | 7.14 Million SEK | -8.85% |
| 2014 Q1 | 7.84 Million SEK | 146.39% |
| 2013 Q2 | 6.27 Million SEK | -15.16% |
| 2013 Q1 | 7.39 Million SEK | 102.71% |
| 2013 FY | - SEK | -6.47% |
| 2013 Q4 | 3.18 Million SEK | -48.89% |
| 2013 Q3 | 6.22 Million SEK | -0.77% |
| 2012 Q3 | 6 Million SEK | 34.67% |
| 2012 FY | - SEK | -14.57% |
| 2012 Q1 | 10.55 Million SEK | 153.21% |
| 2012 Q2 | 4.46 Million SEK | -57.72% |
| 2012 Q4 | 3.64 Million SEK | -39.29% |
| 2011 Q2 | 8.35 Million SEK | 1.09% |
| 2011 Q3 | 7.66 Million SEK | -8.28% |
| 2011 Q4 | 4.16 Million SEK | -45.64% |
| 2011 FY | - SEK | 3.15% |
| 2011 Q1 | 8.26 Million SEK | 71.34% |
| 2010 Q1 | 4.56 Million SEK | 0.0% |
| 2010 FY | - SEK | 38.58% |
| 2010 Q3 | 13.91 Million SEK | 210.88% |
| 2010 Q4 | 4.82 Million SEK | -65.33% |
| 2010 Q2 | 4.47 Million SEK | -1.82% |
| 2009 FY | - SEK | 15.7% |
| 2008 FY | - SEK | 51.34% |
| 2007 FY | - SEK | 489.93% |
| 2006 FY | - SEK | -91.85% |
| 2005 FY | - SEK | -22.61% |
| 2004 FY | - SEK | 57.97% |
| 2003 FY | - SEK | 33.08% |
| 2002 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | 944.438% |
| AlzeCure Pharma AB (publ) | -37.86 Million SEK | 405.303% |
| BioGaia AB (publ) | 466.19 Million SEK | 75.201% |
| Enzymatica AB (publ) | -41.12 Million SEK | 381.144% |
| Enorama Pharma AB (publ) | -43.05 Million SEK | 368.534% |
| Gabather AB (publ) | 37 Thousand SEK | -312364.865% |
| Klaria Pharma Holding AB (publ.) | -14.77 Million SEK | 882.749% |
| Moberg Pharma AB (publ) | -26.95 Million SEK | 528.838% |
| Nanexa AB (publ) | -70.79 Million SEK | 263.315% |
| Newbury Pharmaceuticals AB (publ) | -12.34 Million SEK | 1036.888% |
| ODI Pharma AB | 1.36 Million SEK | -8355.107% |
| Orexo AB (publ) | -22 Million SEK | 625.509% |
| Swedencare AB (publ) | 484 Million SEK | 76.113% |
| Swedish Orphan Biovitrum AB (publ) | 7.23 Billion SEK | 98.402% |
| Toleranzia AB | -7.39 Million SEK | 1662.747% |
| Vivesto AB | -89.75 Million SEK | 228.804% |